Page last updated: 2024-08-17

carbostyril and Inflammatory Breast Neoplasms

carbostyril has been researched along with Inflammatory Breast Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Alvarez, RH; Andreopoulou, E; Cristofanilli, M; Fehn, K; Fineberg, S; Han, HS; Hershman, DL; Pellegrino, CM; Raptis, G; Sparano, JA; Vahdat, LT; Valero, V; Vigoda, IS; Wright, JJ1

Trials

1 trial(s) available for carbostyril and Inflammatory Breast Neoplasms

ArticleYear
Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
    Breast cancer research and treatment, 2013, Volume: 141, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Farnesyl-Diphosphate Farnesyltransferase; Female; Humans; Inflammatory Breast Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Quinolones; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome

2013